Prognostic factors for patients with small cell lung carcinoma

Paesmans, Marianne; Sculier, Jean-Paul; Lecomte, Jacques; Thiriaux, J; Libert, P; Sergysels, Roger; Bureau, G.; Dabouis, G; Cutsem, O Van; Mommen, Paul; Ninane, Vincent; Klastersky, Jean

doi:10.1002/1097-0142(20000801)89:3<523::aid-cncr7>3.0.co;2-6

Cited by 200 publications

(30 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, patients with limited disease survive longer than those with extensive disease, and with a combined treatment approach up to 20% of patients with limited disease can be cured. Early diagnosis, staging, age at diagnosis and performance status have been shown to have prognostic value and guide treatment [3,4]. Accurate methods for initial staging and follow-up after initial therapy are therefore necessary.…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of [ 18 F]FDG-PET imaging in small cell lung cancer

Pandit

Gönen

Krug

et al. 2003

European Journal of Nuclear Medicine and Molecular Imaging

154

View full text Add to dashboard Cite

Positron emission tomography (PET) utilizing fluorine-18 fluorodeoxyglucose (FDG) has been used in the evaluation of non-small cell lung cancer (NSCLC). Recently its use in the staging of small cell lung cancer (SCLC) has been reported. However, the prognostic value of FDG-PET imaging in SCLC has not been studied. We performed a retrospective analysis to assess this, with the following hypotheses: (1) PET-positive patients would have a less favorable prognosis than PET-negative patients and (2) a high standardized uptake value (SUV) would be associated with a poor prognosis. Retrospective review of a mixed population of treated and untreated patients imaged between 1995 and 2000 was performed. Results of 62 scans in 46 patients were analyzed. There were 8 untreated and 38 treated patients. Findings were correlated with pathology, computed tomography/magnetic resonance imaging and clinical data. The sensitivity of PET scanning was 100% with pathological correlation. The prognostic value of a positive PET study was determined. Overall survival in PET-positive cases was significantly worse than that in PET-negative cases ( P=0.0108). Correlation of SUV(max) with survival showed a significant negative correlation ( P=0.0021). In the eight untreated patients, scans were strongly positive and in all cases the scan results concurred with the final clinical stage assigned on the basis of conventional methods. We conclude that FDG-PET imaging provides prognostic information in treated patients. A positive study and a high SUV(max) are significantly associated with poor survival. Additionally, FDG-PET may be helpful in staging and follow-up.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic value of [ 18 F]FDG-PET imaging in small cell lung cancer

Pandit

Gönen

Krug

et al. 2003

European Journal of Nuclear Medicine and Molecular Imaging

154

View full text Add to dashboard Cite

show abstract

“…For example, Van Glabbeke et al (34) identified that elevated PNC was correlated with chemoresistance in GIST. An additional study demonstrated that a normal neutrophil ratio was independently associated with the response to chemotherapy in SCLC (41). Previous research also demonstrated that NLR was correlated with chemotherapeutic response (33,42).…”

Section: Discussionmentioning

confidence: 82%

Predictive value of inflammatory indexes on the chemotherapeutic response in patients with unresectable lung cancer: A retrospective study

Sun

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

“…However, response to treatment, in particular, complete response, has been suggested as the major indicator of long-term survival (Paesmans et al, 2000). In ED patients the doublet PE produced complete response rates ranging from 4 to 23% (Evans et al, 1985;Roth et al, 1992;Pujol et al, 2001) and the triplets CDE (cyclophosphamide, doxorubicin and i.v.…”

Section: Discussionmentioning

confidence: 99%

Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I–II study

et al. 2006

View full text Add to dashboard Cite

The aim of this study was to evaluate feasibility and toxicity of escalating doses of epirubicin and paclitaxel plus fixed dose of etoposide and to define the activity of the triplet in extensive disease small-cell lung cancer. Thirteen patients entered the phase I study: the maximum tolerated doses were epirubicin (EpiDX) 90 mg m À2 and paclitaxel (P) 175 mg m À2 with febrile neutropenia as dose-limiting toxicity. The recommended schedule for this regimen for the phase II study was EpiDX 75 mg m À2 , P 175 mg m À2 , etoposide (E) 100 mg m À2 intravenous (fixed dose) days 1 -3 with courses repeated every 21 days. The prophylactic use of colonystimulating factors (CSFs) was not allowed. Twenty patients entered the phase II trial: median age was 61 years (range 50 -70), median Eastern Cooperative Oncology Group performance status 0 (0 -2); nine patients had visceral disease and 17 had more than two metastatic sites. A total of 100 courses were administered with a median of 5 (range 1 -6) per patients. Main toxicity (NCI-CTC) was myelosuppression: neutropenia grades 3 and 4 in 16 and 35% of the courses, respectively. Seven episodes of febrile neutropenia were documented and one patient required hospital admission. Nonhaematological toxicity was moderate. Seven out of 19 evaluable patients achieved a complete response (37%), nine patients (47.3%) a partial response with an overall response rate of 84.2% ((95% confidence interval ¼ 60.4 -96.6)). In this poor prognostic population of patients the triplet epirubicin/paclitaxel/ etoposide showed high antitumour activity with mild nonhaematological side effects. The use of CSFs should be able to improve the haematological profile.

show abstract

Prognostic factors for patients with small cell lung carcinoma

Cited by 200 publications

References 38 publications

Prognostic value of [ 18 F]FDG-PET imaging in small cell lung cancer

Prognostic value of [ 18 F]FDG-PET imaging in small cell lung cancer

Predictive value of inflammatory indexes on the chemotherapeutic response in patients with unresectable lung cancer: A retrospective study

Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I–II study

Contact Info

Product

Resources

About